6533b836fe1ef96bd12a0816
RESEARCH PRODUCT
Protection of HeLa‐T4 + cells against human immunodeficiency virus (HIV) infection after stable transfection with HIV LTR‐2‘,5‘‐oligoadenylate synthetase hybrid gene 1
Yoshiyuki KuchinoDurdica UgarkovicWerner E. G. M�llerHeinz C. SchröderTakashi OkamotoHelmut Merzsubject
Expression vector2'-5'-OligoadenylatevirusesTransfectionBiologyBiochemistryVirologyMolecular biologyVirusLong terminal repeatGene productchemistry.chemical_compoundchemistryGeneticsMolecular BiologyHygromycin BSelectable markerBiotechnologydescription
An expression vector (pU3R-III/2-5AS) of human 2',5'-oligoadenylate (2-5A) synthetase was constructed in which a cDNA encoding an active form of the enzyme was located 3' to a 3'-long terminal repeat (LTR) of human immunodeficiency virus type 1 (HIV-1). The LTR-directed expression of this hybrid DNA could be activated in trans by the HIV tat gene product. This vector was used for transfection of HeLa-T4+ cells, which are permissive to HIV infection, as well as of normal HeLa cells. HIV replication after infection of the CD4-receptor-bearing HeLa-T4+ cells with HIV-1 was found to be strongly reduced when drug-selected cells cotransfected with pU3R-III/2-5AS and a hygromycin B resistance gene containing plasmid were used. In nontransfected cultures or after transfection with the selectable marker plasmid only, about 60% p17- and p24-positive cells were found 5 days after infection. However, after stable transfection with pU3R-III/2-5AS the number of positive cells was decreased to about 2%. The reverse tran...
year | journal | country | edition | language |
---|---|---|---|---|
1990-10-01 | The FASEB Journal |